These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 33654205)

  • 1. BET proteolysis targeted chimera-based therapy of novel models of Richter Transformation-diffuse large B-cell lymphoma.
    Fiskus W; Mill CP; Perera D; Birdwell C; Deng Q; Yang H; Lara BH; Jain N; Burger J; Ferrajoli A; Davis JA; Saenz DT; Jin W; Coarfa C; Crews CM; Green MR; Khoury JD; Bhalla KN
    Leukemia; 2021 Sep; 35(9):2621-2634. PubMed ID: 33654205
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combination of Ibrutinib and ABT-199 in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma.
    Kuo HP; Ezell SA; Schweighofer KJ; Cheung LWK; Hsieh S; Apatira M; Sirisawad M; Eckert K; Hsu SJ; Chen CT; Beaupre DM; Versele M; Chang BY
    Mol Cancer Ther; 2017 Jul; 16(7):1246-1256. PubMed ID: 28428442
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HDAC inhibitor chidamide synergizes with venetoclax to inhibit the growth of diffuse large B-cell lymphoma via down-regulation of MYC, BCL2, and TP53 expression.
    Luo C; Yu T; Young KH; Yu L
    J Zhejiang Univ Sci B; 2022 Aug; 23(8):666-681. PubMed ID: 35953760
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination Targeted Therapy in Relapsed Diffuse Large B-Cell Lymphoma.
    Melani C; Lakhotia R; Pittaluga S; Phelan JD; Huang DW; Wright G; Simard J; Muppidi J; Thomas CJ; Ceribelli M; Tosto FA; Yang Y; Xu W; Davies-Hill T; Pack SD; Peer CJ; Arisa O; Mena E; Lindenberg L; Bergvall E; Portell CA; Farah RJ; Lee ST; Pradhan A; Morrison C; Tadese A; Juanitez AM; Lu C; Jacob A; Simmons H; Figg WD; Steinberg SM; Jaffe ES; Roschewski M; Staudt LM; Wilson WH
    N Engl J Med; 2024 Jun; 390(23):2143-2155. PubMed ID: 38899693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting of BCL2 Family Proteins with ABT-199 and Homoharringtonine Reveals BCL2- and MCL1-Dependent Subgroups of Diffuse Large B-Cell Lymphoma.
    Klanova M; Andera L; Brazina J; Svadlenka J; Benesova S; Soukup J; Prukova D; Vejmelkova D; Jaksa R; Helman K; Vockova P; Lateckova L; Molinsky J; Maswabi BC; Alam M; Kodet R; Pytlik R; Trneny M; Klener P
    Clin Cancer Res; 2016 Mar; 22(5):1138-49. PubMed ID: 26467384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ibrutinib combined with venetoclax for the treatment of relapsed/refractory diffuse large B cell lymphoma.
    Zhou Z; Zhang L; Wang X; Li X; Li L; Fu X; Zhang X; Li Z; Sun Z; Zhang M
    Ann Hematol; 2021 Jun; 100(6):1509-1516. PubMed ID: 33900450
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synergistic effect of venetoclax and ibrutinib on ibrutinib-resistant ABC-type DLBCL cells.
    Jin F; He L; Chen Y; Tian W; Liu L; Ge L; Qian W; Xia L; Yang M
    Braz J Med Biol Res; 2024; 57():e13278. PubMed ID: 39383379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategic Therapeutic Targeting to Overcome Venetoclax Resistance in Aggressive B-cell Lymphomas.
    Pham LV; Huang S; Zhang H; Zhang J; Bell T; Zhou S; Pogue E; Ding Z; Lam L; Westin J; Davis RE; Young KH; Medeiros LJ; Ford RJ; Nomie K; Zhang L; Wang M
    Clin Cancer Res; 2018 Aug; 24(16):3967-3980. PubMed ID: 29666304
    [No Abstract]   [Full Text] [Related]  

  • 9. Targeted inhibition of PI3Kα/δ is synergistic with BCL-2 blockade in genetically defined subtypes of DLBCL.
    Bojarczuk K; Wienand K; Ryan JA; Chen L; Villalobos-Ortiz M; Mandato E; Stachura J; Letai A; Lawton LN; Chapuy B; Shipp MA
    Blood; 2019 Jan; 133(1):70-80. PubMed ID: 30322870
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synergistic induction of apoptosis in high-risk DLBCL by BCL2 inhibition with ABT-199 combined with pharmacologic loss of MCL1.
    Li L; Pongtornpipat P; Tiutan T; Kendrick SL; Park S; Persky DO; Rimsza LM; Puvvada SD; Schatz JH
    Leukemia; 2015 Aug; 29(8):1702-12. PubMed ID: 25882699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Richter transformation driven by Epstein-Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia.
    García-Barchino MJ; Sarasquete ME; Panizo C; Morscio J; Martinez A; Alcoceba M; Fresquet V; Gonzalez-Farre B; Paiva B; Young KH; Robles EF; Roa S; Celay J; Larrayoz M; Rossi D; Gaidano G; Montes-Moreno S; Piris MA; Balanzategui A; Jimenez C; Rodriguez I; Calasanz MJ; Larrayoz MJ; Segura V; Garcia-Muñoz R; Rabasa MP; Yi S; Li J; Zhang M; Xu-Monette ZY; Puig-Moron N; Orfao A; Böttcher S; Hernandez-Rivas JM; Miguel JS; Prosper F; Tousseyn T; Sagaert X; Gonzalez M; Martinez-Climent JA
    J Pathol; 2018 May; 245(1):61-73. PubMed ID: 29464716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax.
    Gángó A; Kiss R; Farkas P; Hanna E; Demeter J; Deák B; Lévai D; Kotmayer L; Alpár D; Matolcsy A; Bödör C; Mátrai Z; Timár B
    Pathology; 2022 Feb; 54(1):95-103. PubMed ID: 34332791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-1 Expression in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Large B-cell Richter Transformation (DLBCL-RT): A Characteristic Feature of DLBCL-RT and Potential Surrogate Marker for Clonal Relatedness.
    He R; Ding W; Viswanatha DS; Chen D; Shi M; Van Dyke D; Tian S; Dao LN; Parikh SA; Shanafelt TD; Call TG; Ansell SM; Leis JF; Mai M; Hanson CA; Rech KL
    Am J Surg Pathol; 2018 Jul; 42(7):843-854. PubMed ID: 29762141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of Enzastaurin and Ibrutinib synergistically induces anti-tumor effects in diffuse large B cell lymphoma.
    He Y; Li J; Ding N; Wang X; Deng L; Xie Y; Ying Z; Liu W; Ping L; Zhang C; Song Y; Zhu J
    J Exp Clin Cancer Res; 2019 Feb; 38(1):86. PubMed ID: 30777096
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting eIF4F translation initiation complex with SBI-756 sensitises B lymphoma cells to venetoclax.
    Herzog LO; Walters B; Buono R; Lee JS; Mallya S; Fung A; Chiu H; Nguyen N; Li B; Pinkerton AB; Jackson MR; Schneider RJ; Ronai ZA; Fruman DA
    Br J Cancer; 2021 Mar; 124(6):1098-1109. PubMed ID: 33318657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targetable genetic alterations of
    Jain N; Hartert K; Tadros S; Fiskus W; Havranek O; Ma MCJ; Bouska A; Heavican T; Kumar D; Deng Q; Moore D; Pak C; Liu CL; Gentles AJ; Hartmann E; Kridel R; Smedby KE; Juliusson G; Rosenquist R; Gascoyne RD; Rosenwald A; Giancotti F; Neelapu SS; Westin J; Vose JM; Lunning MA; Greiner T; Rodig S; Iqbal J; Alizadeh AA; Davis RE; Bhalla K; Green MR
    Sci Transl Med; 2019 Jun; 11(497):. PubMed ID: 31217338
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activation of unfolded protein response overcomes Ibrutinib resistance in diffuse large B-cell lymphoma.
    Zhang XT; Hu XB; Wang HL; Kan WJ; Xu L; Wang ZJ; Xiang YQ; Wu WB; Feng B; Li JN; Gao AH; Dong TC; Xia CM; Zhou YB; Li J
    Acta Pharmacol Sin; 2021 May; 42(5):814-823. PubMed ID: 32855532
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Heterogeneous Pattern of Dependence on Anti-Apoptotic BCL-2 Family Proteins upon CHOP Treatment in Diffuse Large B-Cell Lymphoma.
    de Jong MRW; Langendonk M; Reitsma B; Nijland M; van den Berg A; Ammatuna E; Visser L; van Meerten T
    Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31801186
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sirt6 promotes tumorigenesis and drug resistance of diffuse large B-cell lymphoma by mediating PI3K/Akt signaling.
    Yang J; Li Y; Zhang Y; Fang X; Chen N; Zhou X; Wang X
    J Exp Clin Cancer Res; 2020 Jul; 39(1):142. PubMed ID: 32711549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The BET bromodomain inhibitor CPI203 overcomes resistance to ABT-199 (venetoclax) by downregulation of BFL-1/A1 in in vitro and in vivo models of MYC+/BCL2+ double hit lymphoma.
    Esteve-Arenys A; Valero JG; Chamorro-Jorganes A; Gonzalez D; Rodriguez V; Dlouhy I; Salaverria I; Campo E; Colomer D; Martinez A; Rymkiewicz G; Pérez-Galán P; Lopez-Guillermo A; Roué G
    Oncogene; 2018 Apr; 37(14):1830-1844. PubMed ID: 29353886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.